Loading...
Loading...
ARGX| Name | Value |
|---|---|
| Revenues | 329.8M |
| Cost of Revenue | 36.0M |
| Gross Profit | 293.8M |
| Operating Expense | 373.6M |
| Operating I/L | -80.6M |
| Other Income/Expense | -2.7M |
| Interest Income | 30.0M |
| Pretax | -83.3M |
| Income Tax Expense | -10.6M |
| Net Income/Loss | -72.6M |
argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases. Its lead product candidate, efgartigimod, is in Phase III clinical trials for various conditions. The company also has a pipeline of immunology innovation programs targeting hematological cancer, severe autoimmune indications, airway inflammation, and autoimmune diseases. Additionally, it has partnered product candidates for the treatment of cancer and other conditions. argenx SE has strategic partnerships and collaboration agreements with several organizations. The company generates revenue through the development and potential commercialization of its therapeutic products and through partnerships and collaborations.
